Revised Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials

α
Matthew Chukwuma Michael
Matthew Chukwuma Michael
σ
Matthew Chukwuma Michael; Oyeka I. C. A
Matthew Chukwuma Michael; Oyeka I. C. A
ρ
;  Ajibabe Bright
; Ajibabe Bright
α Delta State Polytechnic Ogwashi-Uku

Send Message

To: Author

Revised Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials

Article Fingerprint

ReserarchID

V1Y28

Revised Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

This paper proposes and presents a method for the estimation of approval probabilities of new drug or product. The proposed method assumes that three evaluation communities are used to assess and evaluate the quality of a new drug or product and that the evaluation is done by the committees in three period phased clinical trials of the drug or product using matched samples of subjects at each phase. Estimates of absolute and conditional approval probabilities by various combination evaluation committees at each phase of clinical trials are provided. Test statistics are also developed testing desired hypothesis at each of the phased clinical trials. The proposed method is illustrated with some sample data. It is shown in terms of estimated probability that it is more difficult for all three evaluation committees to be in complex agreement to approve or not approve a new drug or product than for fewer evaluation committees to grant approval.

References

12 Cites in Article
  1. K Rising,P Bacchetti,L Bero (2009). Reporting Bias in Drug Trials Submitted to the Food and Drug Administration Review of Publication and Presentation.
  2. Jogarao Gobburu,Lawrence Lesko (2009). Quantitative Disease, Drug, and Trial Models.
  3. S Chow,J Liu (2004). Design and Analysis of Clinical Trials: Concept and Methodologies.
  4. Toby Huff (2003). The Rise of Early Modern Science.
  5. Ilya Lipkovich,David Adams,Craig Mallinckrodt,Doug Faries,David Baron,John Houston (2008). Evaluating dose response from flexible dose clinical trials.
  6. S Pocock (2004). Clinical Trials. A Practical Approach.
  7. V Gebski,E Beller,A Keech (2001). Randomized Trials: Elements of a Good Study.
  8. G Koren,M Boloja,D Long,Y Feldman,N Shear (1998). Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester.
  9. Ann Dally,Thalidomide (1998). Thalidomide: was the tragedy preventable?.
  10. G Koren,A Pastuszak (1990). Prevention of unnecessary pregnancy termination by counselling women on drug, chemical and radiation exposure during the first trimester.
  11. G Koren,A Pastuszak,I Sinya (1998). Drugs in pregnancy.
  12. R Collier (2009). Drug development cost estimates hard to swallow.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Matthew Chukwuma Michael. 2017. \u201cRevised Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials\u201d. Global Journal of Science Frontier Research - F: Mathematics & Decision GJSFR-F Volume 17 (GJSFR Volume 17 Issue F5): .

Download Citation

Issue Cover
GJSFR Volume 17 Issue F5
Pg. 33- 49
Journal Specifications

Crossref Journal DOI 10.17406/GJSFR

Print ISSN 0975-5896

e-ISSN 2249-4626

Keywords
Classification
GJSFR-F Classification: MSC 2010: 97K80
Version of record

v1.2

Issue date

August 24, 2017

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 3484
Total Downloads: 1605
2026 Trends
Related Research

Published Article

This paper proposes and presents a method for the estimation of approval probabilities of new drug or product. The proposed method assumes that three evaluation communities are used to assess and evaluate the quality of a new drug or product and that the evaluation is done by the committees in three period phased clinical trials of the drug or product using matched samples of subjects at each phase. Estimates of absolute and conditional approval probabilities by various combination evaluation committees at each phase of clinical trials are provided. Test statistics are also developed testing desired hypothesis at each of the phased clinical trials. The proposed method is illustrated with some sample data. It is shown in terms of estimated probability that it is more difficult for all three evaluation committees to be in complex agreement to approve or not approve a new drug or product than for fewer evaluation committees to grant approval.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Revised Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials

Matthew Chukwuma Michael; Oyeka I. C. A
Matthew Chukwuma Michael; Oyeka I. C. A
;  Ajibabe Bright
; Ajibabe Bright

Research Journals